Long-term Outcomes of Antiviral Therapy in Patients With Advanced Chronic HBV Infection.

Authors :: Lee HW
Park JY
Kim SG
Tak WY
Yim HJ
Jang BK
Kim MY
Kim BI
Lee JW
Yoon KT
Cheong JY
Kwon SY
Kim TY
Bae SH
Seo YS
Kwon JH
Kim DJ
Kim JK
Jeong SW
Myoung S
Ahn SH
Han KH
Source :: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association [Clin Gastroenterol Hepatol] 2019 Dec; Vol. 17 (13), pp. 2811-2813.e1. Date of Electronic Publication: 2019 Feb 05.
Publication Year :: 2019
Abstract: Hepatitis B virus (HBV) suppression with nucleot(s)ide analogue therapy reduces the risk of hepatic decompensation and hepatocellular carcinoma (HCC) in patients with advanced liver disease. <superscript>1</superscript> In the present era of potent antiviral therapies, the prognostic significance of the serum HBV DNA level as a biological gradient has substantially diminished; the majority of treated patients achieve virologic suppression. <superscript>2,3</superscript> After control of viremia, a higher baseline fibrosis level is a useful predictor for disease progression. <superscript>4</superscript> Few "prospective" studies on the effects of antiviral agents, especially in chronic hepatitis B (CHB) patients with advanced liver disease, have been reported.<br /> (Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.)

Language :: English
ISSN :: 1542-7714
Volume :: 17
Issue :: 13
Database :: MEDLINE
Journal :: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Publication Type :: Academic Journal
Accession number :: 30731195
Full Text :: https://doi.org/10.1016/j.cgh.2019.01.044

Full Text Access

Tools